In the realm of high-performing stocks, Tevogen Bio Holdings (TVGN) surged by 187.14%, marking a three-day increase of 320.36%. Tevogen Bio has announced plans to unveil its pipeline portfolio with over $1 billion in revenue potential starting from October 14, 2024.

Rani Therapeutics (RANI) rose by 57.43%, despite a price target reduction to $9 by an HC Wainwright analyst who maintained a buy rating for the company.

Longboard Pharmaceuticals (LBPH) saw a 51.65% increase, with shares climbing steadily for three days, resulting in a 76.83% gain. This surge is attributed to a broader market rally, with the Dow Jones index soaring by over 200 points.

Inventiva (IVA) gained 41.27%, continuing its three-day rise to a total of 61.92%. The French pharmaceutical company earned a buy rating from Stifel, with analysts optimistic about its liver disease treatment developments.

In China, Dashu Cloud (DSY) increased by 38.52% following the People's Bank of China's announcement to expedite financial policy implementations, aiming for comprehensive policy execution.

On the flip side, Future Group (TWG) experienced a steep decline of 35.57% due to a financial fraud scandal denting investor confidence and concerns over its future profitability, exerting massive pressure on its stock price.

Tiger Broker (TIGR) fell by 15.20%. Despite a 32% year-on-year revenue increase in Q2, the company faced significant net profit reductions.

Agora (API) dropped by 10.12% after opting for Wormhole as the core interoperability solution for the AUSD stablecoin.

Xpeng Motors (XPEV) decreased by 9.77% amid weakened trading of U.S.-listed Chinese stocks due to uncertainty surrounding fiscal stimulus measures.

Torrid Holdings (CURV) saw a decline of 9.46% as the company faced turbulence following the dismissal of its Chief Creative Officer, which impacted investor sentiment negatively.